News for Ocugen, Inc. (OCGN.MX)

Ocugen's (OCGN) gene therapy OCU410ST gains rare pediatric disease designation from the FDA, paving the way for expedited reviews. Analyst predictions s

H.C. Wainwright has adjusted its price target for Ocugen (OCGN), reducing it from $8 to $7, but maintained a Buy rating on the stock. This decision follows the

On May 12, 2025, HC Wainwright & Co., through its analyst Swayampakula Ramakanth, reaffirmed a 'Buy' rating for Ocugen (OCGN). The firm has chosen to maintain i

Ocugen (OCGN), a biopharmaceutical company, has maintained its "Buy" rating from Chardan Capital as of May 12, 2025. This consistent rating reflects the continu

Release Date: May 09, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ocugen Inc (OCGN)

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NOCGN.OQ - Ocugen IncQ1 2025 Ocugen Inc Earnings CallMay 09, 2025 / 12:30PM GMT ===============

Call Start: 8:30 January 1, 0000 8:59 AM ETOcugen, Inc.

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential B

Ocugen (OCGN) reported a notable increase in its first-quarter revenue, reaching $1.481 million, up from $1.014 million during the same period last year. The co

Ocugen (OCGN) reports Q1 2025 net loss of $0.05 per share with operating expenses reaching $16.0 million. Cash reserves stand at $38.1 million as of Mar

**media[620324]**

OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ETCompany ParticipantsTiffany Hamilton - Head, Corporate...

Conference Call and Webcast Today at 8:30 a.m. ET Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt di

Quarterly Revenue: $0.76 million, surpassing the estimated $0.30 million.Quarterly EPS: Reported a net loss of $0.05 per share, matching the estimated loss of

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) —

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a pioneering biotechnology leader in gene therapies for blindnes

Atkore Inc. (NYSE: ATKR):

**media[546596]**